You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

406 Results
Guidelines and Advice
Status: Current
ID: GL 17-12
Version: N/A
Sep 2019
Document
Nov 2019
Document
Nov 2019
Document
Nov 2019
Document
Nov 2019
Document
Nov 2019
Document
Nov 2019
Document
Nov 2019
Drug
Other Name(s): Unituxin®
Quick Link(s):
Drug Monograph
Jun 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
iBRUtinib (Unfunded),
riTUXimab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2020
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
darolutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2025
Statistical Reports

Pages